Earnings Per Share

12 Months Ended

Sep. 30, 2023

Earnings Per Share [Abstract]

Earnings Per Share

EARNINGS PER SHARE

The following table presents the computation of basic and diluted earnings per share for the years ended September 30, 2023, 2022 and 2021.

	Year Ended September 30,
	2023		2022		2021
	(in thousands, except per share amounts)
Numerator:
Net loss attributable to Arrowhead Pharmaceuticals, Inc.	$	(205,275)	$	(176,063)	$	(140,848)
Denominator:
Weighted-average basic shares outstanding	106,750		105,426		103,745
Effect of dilutive securities	—		—		—
Weighted-average diluted shares outstanding	106,750		105,426		103,745
Basic earnings per share	$	(1.92)	$	(1.67)	$	(1.36)
Diluted earnings per share	$	(1.92)	$	(1.67)	$	(1.36)

Potentially dilutive securities representing approximately 4,053,000, 3,885,000 and 2,063,000 shares of common stock were excluded from the computation of diluted earnings per share for the years ended September 30, 2023, 2022 and 2021, respectively, because their effect would have been anti-dilutive.